

March 16, 2021

Cuorips Inc.

Private Placement of New Shares

Tokyo, Japan (March 16, 2021) - Cuorips Inc. (HO: Chuo-ku, Tokyo; President: Takayuki Kusanagi) hereby announce that roughly 1.6 billion yen was raised through private placement of new shares to JIC Venture Growth Investments Co., Ltd. (HO: Chiyoda-ku, Tokyo), JAFCO SV6 Investment Limited Partnership (HO : Minato-ku, Tokyo), JAFCO SV6 STAR Investment Limited Partnership (HO : Minato-ku, Tokyo), Kyoto-University-Venture NVCC No.2 Investment Limited Partnership (HO : Chiyoda-ku, Tokyo) , Osaka-University-Venture NVCC No.1 Investment Limited Partnership (HO : Chiyoda-ku, Tokyo) , FUJIFILM Corporation (HO : Minato-ku, Tokyo) and CellSource Co., Ltd. (HO : shibuya-ku, Tokyo) etc..

(For reference)

1: Cuorips Inc.

Cuorips Inc. is a start-up company, established in March 2017, based on technology and research results of Osaka University, for the purpose of development and commercialization of iPS cell-derived cardiomyocyte sheets.

Cuorips is developing production process technology of iPS cell-derived cardiomyocyte sheets to increase efficiency, and to obtain Japanese government approval as the world's 1st regenerative medicines for severe heart failures.

2: iPS cell-derived cardiomyocyte sheets

An allogeneic cell therapeutic product mainly composed of cardiomyocytes (iPS myocardium), differentiated from human iPS cells are processed into a sheet and will be transplanted onto the surface of patient's heart. Therapeutic effects such as improvement of heart function and recovery of heart failure can be expected to the patients with severe heart failure such have no treatment options.

[Inquiries regarding this matter]

Cuorips Inc. Public Relations: Kobayashi and Hirata

Website: <https://cuorips.co.jp>

Contact Info. E-mail: info@cuorips.co.jp